Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment

Conclusions: Our meta-analysis demonstrates that compared with chemotherapy, pembrolizumab may result in a higher risk of all-grade immune-mediated colitis. PD-1/PD-L1 inhibitor treatment in NSCLC patients, but not in melanoma patients, increases the risk of all-grade colitis incidence.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Qiang Su, Xiaochen Zhang, Xinhua Shen, Yanli Hou, Zhigang Sun, Zu Hua Gao Tags: Research Paper Source Type: research